Last €46.85 EUR
Change Today +0.147 / 0.31%
Volume 28.0
RDDA On Other Exchanges
Symbol
Exchange
New York
Natl India
Frankfurt
Mexico
As of 9:57 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

doctor reddy's lab-adr (RDDA) Snapshot

Open
€46.06
Previous Close
€46.70
Day High
€47.03
Day Low
€45.99
52 Week High
01/23/15 - €48.96
52 Week Low
05/21/14 - €27.66
Market Cap
8.0B
Average Volume 10 Days
204.9
EPS TTM
--
Shares Outstanding
170.3M
EX-Date
08/1/14
P/E TM
--
Dividend
€0.24
Dividend Yield
0.46%
Current Stock Chart for DOCTOR REDDY'S LAB-ADR (RDDA)

Related News

No related news articles were found.

doctor reddy's lab-adr (RDDA) Related Businessweek News

No Related Businessweek News Found

doctor reddy's lab-adr (RDDA) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment is involved in the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. Its differentiated formulations portfolio consists of new, synergistic combinations, and technologies that enhance safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The company’s therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. It also operates in North America, Europe, Russia, other countries of the former Soviet Union, and internationally. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

18,421 Employees
Last Reported Date: 06/26/14
Founded in 1984

doctor reddy's lab-adr (RDDA) Top Compensated Officers

Co-Chairman, Chief Executive Officer, Member ...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 7.7M
Compensation as of Fiscal Year 2014.

doctor reddy's lab-adr (RDDA) Key Developments

Cadilla, Lupin, Cipla, Sun Pharma, Dr Reddy's, Pfizer and Sandoz Reportedly Eyes Takeover Of CLARIS Lifesciences's Injectables Business

Pfizer Limited (BSE:500680), Novartis AG (SWX:NOVN), Lupin Limited (BSE:500257), Cipla Limited (BSE:500087), Dr. Reddy's Laboratories Ltd. (BSE:500124), Sun Pharmaceutical Industries Limited (BSE:524715) and Cadila Healthcare Limited (BSE:532321) are reportedly looking to acquire the injectables business from Claris Lifesciences Limited (BSE:533288).

Dr. Reddy’s Laboratories Ltd. Announces Unaudited Consolidated Cash Flow Results for the Nine Months Ended December 31, 2014; Reports Impairment Charges for the Three Months Ended December 31, 2014

Dr. Reddy’s Laboratories Ltd. announced unaudited consolidated cash flow results for the nine months ended December 31, 2014. For the period, net cash from operating activities was INR 14,772 million against INR 11,375 million a year ago. Expenditure on property, plant and equipment was INR 6,857 million against INR 7,998 million a year ago. Expenditure on other intangible assets was INR 5,731 million against INR 547 million a year ago For the three months ended December 31, 2014, impairment loss on intangible asset was INR 534 million against reversal of impairment loss of INR 497 million a year ago.

Dr. Reddy's Laboratories Ltd. Announces Unaudited Consolidated and Standalone Financial Results for the Third Quarter and Nine Months Ended December 31, 2014; Provides Tax Rate Guidance for the Year 2015

Dr. Reddy’s Laboratories Ltd. announced unaudited consolidated and standalone financial results for the third quarter and nine months ended December 31, 2014. For the quarter, the consolidated company reported revenues of INR 38,431.0 million against INR 35,337.6 million a year ago. Results from operating activities were INR 7,226.7 million against INR 8,644.0 million a year ago. Profit before tax was INR 8,286.2 million against INR 8,705.2 million a year ago. Profit for the period was INR 5,745.3 million against INR 6,184.2 million a year ago. Diluted earnings per share before and after extra-ordinary items were INR 33.61 against INR 36.25 a year ago. EBITDA was INR 10,515 million against INR 10,049 million a year ago. Capital expenditure for the quarter was at INR 2.65 billion. For the nine months, the consolidated company reported revenues of INR 109,484.5 million against INR 97,361.3 million a year ago. Results from operating activities were INR 20,166.4 million against INR 20,175.6 million a year ago. Profit before tax was INR 22,232.4 million against INR 20,537.4 million a year ago. Profit for the period was INR 16,990.2 million against INR 16,696.0 million a year ago. Diluted earnings per share before and after extra-ordinary items were INR 99.42 against INR 97.85 a year ago. EBITDA was INR 28.1 billion. For the quarter, the standalone company reported revenues of INR 21,213.6 million against INR 25,471.1 million a year ago. Profit from ordinary activities before other income, finance costs and exceptional items was INR 262.7 million against INR 8,171.9 million a year ago. Profit before tax was INR 751.0 million against INR 8,591.3 million a year ago. Profit for the period was INR 715.9 million against INR 6,231.7 million a year ago. Diluted earnings per share before and after extra-ordinary items were INR 4.18 against INR 36.47 a year ago. For the nine months, the standalone company reported revenues of INR 72,261.9 million against INR 69,634.5 million a year ago. Profit from ordinary activities before other income, finance costs and exceptional items was INR 12,699.2 million against INR 18,138.7 million a year ago. Profit before tax was INR 13,720.0 million against INR 18,572.5 million a year ago. Profit for the period was INR 11,079.3 million against INR 14,614.1 million a year ago. Diluted earnings per share before and after extra-ordinary items were INR 64.77 against INR 85.53 a year ago. For the year 2015, the company expects annual effective tax rate to remain in the range of 21% to 22%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDDA:GR €46.85 EUR +0.147

RDDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 1,083 INR +50.30
Cipla Ltd/India 682.05 INR +12.20
Croda International PLC 2,729 GBp -21.00
Lonza Group AG SFr.117.50 CHF +0.40
Symrise AG €56.67 EUR -0.304
View Industry Companies
 

Industry Analysis

RDDA

Industry Average

Valuation RDDA Industry Range
Price/Earnings 26.2x
Price/Sales 4.0x
Price/Book 5.4x
Price/Cash Flow 26.1x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOCTOR REDDY'S LAB-ADR, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.